HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Rhea-AI Summary
HCW Biologics (NASDAQ: HCWB) approved a 1-for-6 reverse stock split of its common stock, effective 12:01 a.m. ET on June 30, 2026. Shares will continue trading on Nasdaq under “HCWB” on a split-adjusted basis with new CUSIP 40423R303.
The move is intended to help maintain compliance with Nasdaq Listing Rule 5550(a) Bid Price Rule and other Nasdaq Hearings Panel conditions. Outstanding shares will be reduced from 9,581,079 to approximately 1,596,849, with no change to authorized shares or par value. Fractional shares will be rounded up to whole shares.
Positive
- Reverse split aims to support ongoing Nasdaq Bid Price Rule compliance
- Outstanding shares reduced from 9,581,079 to approximately 1,596,849
- Fractional shares rounded up, each holder receives at least one whole share
Negative
- Nasdaq Hearings Panel required bid-price compliance to avoid potential delisting
- Reverse split indicates prior trading near the $1.00 minimum bid level
News Market Reaction – HCWB
In the Jun 26 session, HCWB declined 8.04%, reflecting a notable negative market reaction. Argus tracked a trough of -23.6% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Stock split Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Reverse stock split | Neutral | +0.3% | 1-for-40 reverse split to address Nasdaq minimum bid price compliance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior stock-split news for HCWB produced only a modest price reaction, suggesting limited historical impact from such actions.
Key Terms
reverse stock split financial
nasdaq capital market regulatory
cusip financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company completed 28 consecutive trading days above
Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings Panel
MIRAMAR, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today announced that its Board of Directors has approved a 1-for-6 reverse stock split of the Company’s common stock, par value
After an appeal, the Company received a decision letter from a Nasdaq Hearings Panel (the “Panel”) on May 29, 2026, which provided a path to compliance with Nasdaq Listing Rule 5550(a) (the “Bid Price Rule”). The primary requirement in the Panel’s decision letter was that the Company’s Common Stock must trade above
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company, except to the extent that the reverse stock split would otherwise result in any of the Company’s stockholders owning a fractional share as described in more detail below.
The reverse stock split will reduce the number of shares of Common Stock issued and outstanding from 9,581,079 (the number of issued and outstanding shares as of June 25, 2026) to approximately 1,596,849. The total authorized number of shares of Common Stock will remain at 250,000,000 shares of Common Stock and the per-share par value will remain at
As of the effective date of the reverse stock split, the number of shares of Common Stock available for issuance under the Company’s equity incentive plans and issuable upon the exercise of stock options and warrants outstanding immediately prior to the reverse stock split will be proportionately affected by the reverse stock split. The exercise prices of the Company’s outstanding options and warrants will be adjusted in accordance with their respective terms.
Equiniti Trust Company LLC (“Equiniti”), the Company’s transfer agent, will act as the exchange agent for the reverse stock split. Those Company stockholders who hold their shares in electronic form do not need to take any action, as the effect of the Reverse Stock Split will automatically be reflected in their accounts with Equiniti. Those stockholders who hold their shares in “street name” will receive instructions from their bank, broker, or nominee.
About HCW Biologics:
HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward-Looking Statements:
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements relating to the timing, consummation, and impact of the reverse stock split, the Company’s ability to maintain compliance with Nasdaq’s minimum bid price requirement, and the actions of third parties, including Equiniti, with respect to the reverse stock split. Actual results could differ from those projected in any forward-looking statement due to numerous factors. Such factors include, among others, our ability to maintain compliance with Nasdaq’s continued listing rules. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the Securities and Exchange Commission, or the SEC, available at www.sec.gov, including, without limitation, the Company’s most recent Annual Report on Form 10-K filed on March 31, 2026, and other SEC filings.
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
